IP Library › Granted Patent US 12,590,320
Granted Patent B2
US 12,590,320 · App. 16/635,863 · Granted Mar 31, 2026

Cellular models of and therapies for ocular diseases

Inventors: Richard R. Yang (Pak Shek Kok, HK); Stephen H Tsang (New York, NY)
Assignee: Reflection Biotechnologies Limited
C12N15/86A61K48/005A61K48/0075A61P27/02C07K14/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,590,320
App. No.
16/635,863
Granted
Mar 31, 2026
Kind
B2
Abstract

Provided herein are methods for treating or preventing diseases of the eye such as Bietti's Crystalline Dystrophy (BCD) using, for example, vectors for delivering a gene encoding a CYP4V2 protein to the retina (for example, to the retinal pigment epithelial (RPE) cells) or using cells comprising such vectors.

Claims (34)

1 . A vector comprising a nucleic acid molecule comprising a sequence encoding a non-mutant or functional cytochrome P450, family 4, subfamily V, polypeptide 2 (CYP4V2) protein or a functional variant thereof having at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 4 operably linked to at least one regulatory sequence, wherein the vector is a recombinant adeno-associated virus (rAAV) vector, wherein any part of the vector shares at least 60% sequence identity with the entirety of any one of the following sequences: SEQ ID NO:60; SEQ ID NO:61; SEQ ID NO:62; SEQ ID NO:63; SEQ ID NO:64; nucleotide (nt) 237-nt 3579 of SEQ ID NO 60; nt 166-nt 3515 of SEQ ID NO 61; nt 166-nt 3515 of SEQ ID NO 62; nt 166-nt 3515 of SEQ ID NO 63; or nt 130-nt 2097 of SEQ ID NO 64.

2 . The vector of claim 1 , wherein the rAAV vector comprises a VP1, VP2, or VP3 capsid protein selected from any serotype of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, or another naturally derived serotype or isolate or clade of AAV, or hybrids, variants or derivatives thereof.

3 . The vector of claim 1 , wherein the rAAV vector comprises a 5′ AAV inverted terminal repeat (ITR) or a 3′ AAV ITR selected from any one of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, or another naturally derived serotype or isolate or clade of AAV, or mutations, chimeras, variants or fusions thereof.

4 . The vector of claim 1 , wherein the rAAV vector is a chimeric AAV, a shuffled AAV, or a capsid-modified AAV.

5 . The vector of claim 1 , wherein the rAAV vector is a pseudotyped AAV.

6 . The vector of claim 1 , wherein the rAAV vector is a hybrid AAV.

7 . The vector of claim 1 , wherein the rAAV vector comprises one or more modifications to one or more naturally derived AAV capsid proteins.

8 . The rAAV vector of claim 7 , wherein the modifications to the AAV capsid protein comprises one or more amino acid residue Y-F, K-R, T-A, S-A or T-V substitutions.

9 . The vector of claim 1 , wherein the rAAV vector is selected from the group consisting of AAV2/5, AAV2/8, AAV2/2, AAV2 (Y444F+Y500F+Y730F), AAV2/1, AAV2/9, AAV2/8 (Y733F), AAV2/6, AAV2/4, AAV2/7, AAV5, AAV2, AAV8, AAV1, AAV9, AAV6, AAV10, AAV3, AAV4, AAV7, AAV11, AAV12, Anc80, AAV 7m8, AAV-DJ, ShH10, AAV-PHP.B, rh10, and a hybrid, a derivative or variant thereof.

10 . The vector of claim 1 , wherein the rAAV vector is a single-stranded AAV vector or a self-complementary AAV (scAAV) vector.

11 . The vector of claim 1 , wherein the sequence encoding the non-mutant or functional CYP4V2 protein or a functional variant thereof has at least 76% sequence identity with the nucleic acid sequence of SEQ ID NO: 1 or 2.

12 . The vector of claim 1 , wherein the at least one regulatory sequence comprises a promoter.

13 . The vector of claim 12 , wherein the promoter is a retinal pigment epithelium (RPE) cell-specific promoter, a photoreceptor-specific promoter, a retinal cell-specific promoter, a corneal cell-specific promoter, an ocular cell-specific promoter, a cell-specific promoter, a tissue-specific promoter, a constitutive promoter, a ubiquitous promoter, a regulated promoter, an inducible promoter, or a derivative, hybrid or combination thereof.

14 . The vector of claim 12 , wherein the promoter is selected from the group consisting of a CAG promoter (also known as CAGGS promoter, CB promoter or CBA promoter), a chicken beta actin promoter, a small CBA (smCBA) promoter, a CB SB promoter, a CBh promoter, a beta-actin promoter, a human beta actin promoter, or an elongation factor 1 alpha short (EFS) promoter, an elongation factor 1 alpha (EF-1 alpha or EF-1a) promoter, a cytomegalovirus (CMV) promoter, a PGK promoter, a UBC promoter, a GUSB promoter, a UCOE promoter, a VMD2 (vitelliform macular dystrophy 2; also known as BEST1) promoter, an RPE65 promoter, a GRK1 promoter, a human interphotoreceptor retinoid-binding protein proximal (IRBP) promoter, a 235 nt fragment of the hIRBP promoter, an RPGR proximal promoter, the red opsin promoter, a red-green opsin promoter, the blue opsin promoter, the mouse opsin promoter, a rhodopsin (Rho) promoter, a beta phosphodiesterase (PDE) promoter, a retinitis pigmentosa (RP1) promoter, the NXNL2/NXNL1 promoter, a retinal degeneration slow/peripherin 2 (Rds/perphZ) promoter, a IRBP/GNAT2 promoter (hIRBP enhancer fused to cone transducin alpha promoter), an Rds (retinal degeneration slow) promoter, an hPDE6b promoter, a VEcad promoter (VE-cadherin/Cadherin 5 (CDH5)/CD144 promoter), a calcium-sensitive promoter, an NFAT promoter, a zinc-inducible sheep metalioihionine (MX) promoter, a dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, a T7 polymerase promoter system, and an ecdysone insect promoter.

15 . The vector of claim 1 , wherein the at least one regulatory sequence comprises a Kozak sequence or a variant thereof.

16 . The vector of claim 1 , wherein the at least one regulatory sequence comprises an enhancer.

17 . The vector of claim 16 , wherein the enhancer comprises a post-transcriptional regulatory element (PRE), an internal ribosome entry site (IRES), an intron regulatory sequence, a mini-intron splice donor/splice acceptor (SD-SA) or a constitutive transport element (CTE).

18 . The vector of claim 16 , wherein the enhancer is selected from the group consisting of a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) enhancer, an Hepatitis B Virus post-transcriptional regulatory element (HPRE or HBVPRE) enhancer, an IRBP enhancer, a Mason-Pfizer Monkey Virus CTE enhancer, a cytomegalovirus (CMV) immediate early enhancer, an SV40 enhancer, and an Avian Leukemia Virus CTE enhancer.

19 . The vector of claim 1 , wherein the at least one regulatory sequence comprises a polyadenylation (polyA) signal.

20 . The vector of claim 19 , wherein the polyA signal is selected from the group consisting of a bovine growth hormone polyadenylation signal (bGH polyA), a small polyA signal (SPA), a human growth hormone polyadenylation signal (hGH polyA), an SV40 polyA signal, an SV40 early polyA signal, and an SV40 late polyA signal.

21 . The vector of claim 1 , wherein the at least one regulatory sequence comprises an upstream enhancer (USE) operably linked to a polyA signal.

22 . The vector of claim 21 , wherein the USE is selected from the group consisting of SV40 late 2xUSE, HIV-1 (Human immunodeficiency virus 1) USE, GHV (Ground squirrel hepatitis virus) USE, Adenovirus (L3) USE, hTHGB (Human prothrombin) USE, an hC2 (Human C2 complement gene) USE, and a derivative, variant and hybrid thereof.

23 . The vector of claim 1 , wherein the at least one regulatory sequence comprises an intron sequence, a UTR sequence, a splice site sequence, an upstream regulatory domain sequence, a response element sequence, an inducible element sequence, an origin of replication sequence, an internal ribosome entry sites (IRES) sequence, a transcription initiation sequence, a termination sequence, an RNA processing sequence, a junction sequence, a linker sequence, a derivative, hybrid or variant thereof.

24 . The vector of claim 1 , wherein the at least one regulatory sequence is heterologous or homologous relative to the CYP4V2 coding sequence whose expression said regulatory sequence regulates.

25 . The vector of claim 1 , wherein the at least one regulatory sequence comprises an organ-specific, tissue-specific or cell-specific microRNA (miRNA) target sequence.

26 . The vector of claim 1 , comprised within a pharmaceutically acceptable carrier and additional components suitable for a specific route of administration or delivery device.

27 . A cell comprising the vector of claim 1 , wherein the cell is a retinal pigment epithelial (RPE) cell, a photoreceptor cell, a photoreceptor progenitor cell, a choroidal cell, a retinal cell, an induced pluripotent stem (iPS) cell, or a stem cell, of or derived from a human subject suffering from Bietti's Crystalline Dystrophy (BCD, a/k/a Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Retinopathy, Bietti's Retinal Dystrophy), or retinitis pigmentosa (RP) or inherited retinal degeneration (IRD) with bi-allelic CYP4V2 mutations.

28 . A method of treating, arresting or preventing Bietti's Crystalline Dystrophy (BCD, a/k/a Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Retinopathy, Bietti's Retinal Dystrophy), or retinitis pigmentosa (RP) or inherited retinal degeneration (IRD) with bi-allelic CYP4V2 mutations in a human subject in need thereof, the method comprising delivering, to the human subject's retina, a therapeutically effective amount of the cell of claim 27 .

29 . A method of treating, arresting or slowing progression of, rescuing or ameliorating the dysfunction, function loss, dystrophy, disorder, degeneration, atrophy or preventing the death of an ocular cell of a human subject who has Bietti's Crystalline Dystrophy (BCD, a/k/a Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Retinopathy, Bietti's Retinal Dystrophy), or retinitis pigmentosa (RP) or inherited retinal degeneration (IRD) with bi-allelic CYP4V2 mutations, the method comprising transducing the ocular cell with a therapeutically effective amount of the vector of claim 1 .

30 . The method of claim 29 , wherein the ocular cell is a retina cell, a retinal pigment epithelial (RPE) cell, a photoreceptor cell (rod or cone), a choroidal epithelial cell, a corneal epithelium cell, a choroidal cell, a corneal cell, a retina bipolar cell, a photoreceptor progenitor cell, a ganglion cell, or an optic-nerve cell.

31 . A method of treating, arresting or preventing Bietti's Crystalline Dystrophy (BCD, a/k/a Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Retinopathy, Bietti's Retinal Dystrophy), or retinitis pigmentosa (RP) or inherited retinal degeneration (IRD) with bi-allelic CYP4V2 mutations in a human subject in need thereof, the method comprising: delivering to the human subject's retina a therapeutically effective amount of the vector of claim 1 , wherein one or more retinal pigment epithelial (RPE) cells, one or more choroidal cells, or one or more photoreceptor cells of the human subject is transduced with the vector, whereby said disease is treated, arrested or prevented in the human subject.

32 . A method of treating, arresting, or preventing a human subject's disease which is associated with the atrophy, dystrophy, dysfunction, degeneration or death of the retinal pigment epithelial (RPE) cell, the method comprising: delivering to the human subject's retina a therapeutically effective amount of the vector of claim 1 , wherein one or more RPE cells of the human subject is transduced with the vector, whereby said disease is treated, arrested or prevented in the human subject.

33 . A method of treating, arresting or preventing a human subject's disease which is associated with the atrophy, dystrophy, dysfunction, degeneration or death of the retinal pigment epithelial (RPE) cell, the method comprising delivering, to the human subject's retina, a therapeutically effective amount of the RPE cell or stem cell, wherein said RPE cell or stem cell comprises the vector of claim 1 .

34 . A vector comprising a nucleic acid molecule comprising a sequence encoding a non-mutant or functional cytochrome P450, family 4, subfamily V, polypeptide 2 (CYP4V2) protein or a functional variant thereof having at least 99% sequence identity with the amino acid sequence of SEQ ID NO:4 operably linked to at least one regulatory sequence, wherein the vector is a recombinant adeno-associated virus (rAAV) vector, wherein the sequence encoding the non-mutant or functional CYP4V2 protein or a functional variant thereof shares at least 80% sequence identity with SEQ ID NO:2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2020
From: YANG, RICHARD R.; TSANG, STEPHEN H.
To: REFLECTION BIOTECHNOLOGIES LIMITED
Reel/Frame 051744/0460 →
Continuity (2)
Provisional Application 62539473 · Jul 31, 2017
Related Publication 20200255859A1 · Aug 13, 2020
References Cited (198)
US 7282199B2 · Gao et al. · 2007 [cited by applicant]
US 9567376B2 · Cronin et al. · 2017 [cited by applicant]
US 12065663B2 · Yang et al. · 2024 [cited by applicant]
US 20120108651A1 · Bare et al. · 2012 [cited by applicant]
US 20120141422A1 · Barkats · 2012 [cited by applicant]
US 20140010861A1 · Bancel · 2014 [cited by examiner]
US 20150376240A1 · Cronin · 2015 [cited by examiner]
US 20160244837A1 · Bare et al. · 2016 [cited by applicant]
US 20160251648A1 · Wang et al. · 2016 [cited by applicant]
US 20220025369A1 · Fotin-Mleczek et al. · 2022 [cited by examiner]
CN 101812478A · 2010 [cited by applicant]
CN 101812479A · 2010 [cited by applicant]
CN 102618578A · 2012 [cited by applicant]
CN 102649968A · 2012 [cited by applicant]
CN 102676582A · 2012 [cited by applicant]
CN 102676583A · 2012 [cited by applicant]
CN 102994507A · 2013 [cited by applicant]
CN 102994536 · 2013 [cited by applicant]
CN 103374574 · 2013 [cited by applicant]
CN 103374575A · 2013 [cited by applicant]
CN 103374575B · 2015 [cited by examiner]
CN 104450747A · 2015 [cited by applicant]
CN 103468820 · 2015 [cited by applicant]
CN 104745591 · 2015 [cited by applicant]
CN 104745592 · 2015 [cited by applicant]
CN 104745594 · 2015 [cited by applicant]
CN 111500635 · 2020 [cited by applicant]
CN 111500635B · 2020 [cited by applicant]
CN 113015804A · 2021 [cited by applicant]
CN 113106124 · 2021 [cited by applicant]
CN 113166763A · 2021 [cited by applicant]
CN 109136266B · 2022 [cited by applicant]
CN 114381465 · 2022 [cited by applicant]
CN 113260704B · 2022 [cited by applicant]
CN 113106124B · 2022 [cited by applicant]
CN 114381465B · 2024 [cited by applicant]
CN 117916365B · 2025 [cited by applicant]
EP 2872183A1 · 2015 [cited by applicant]
JP 2010035525 · 2010 [cited by applicant]
JP 2017500060 · 2017 [cited by applicant]
JP 2025041881A · 2025 [cited by applicant]
JP 2025090820A · 2025 [cited by applicant]
KR 1020170009812 · 2017 [cited by applicant]
WO WO2004023973A2 · 2004 [cited by examiner]
WO WO2008125846 · 2008 [cited by applicant]
WO WO2014011210A1 · 2014 [cited by applicant]
WO WO2014020149A1 · 2014 [cited by examiner]
WO WO2015048577A2 · 2015 [cited by applicant]
WO WO2015082690A1 · 2015 [cited by applicant]
WO WO2015168666A2 · 2015 [cited by applicant]
WO WO2016097183 · 2016 [cited by applicant]
WO WO2017070632A2 · 2017 [cited by applicant]
WO WO2017072515A1 · 2017 [cited by examiner]
WO WO2017197355A2 · 2017 [cited by applicant]
WO WO2018199287 · 2018 [cited by applicant]
Schambach (Mol Ther, 15(6): 1167-73, 2007). (Year: 2007). [cited by examiner]
Inazawa et al., 2010 (US 20100035758 A1). [cited by examiner]
Li et al., 2013 (GeneSeq Accession No. BBC18586, computer printout, pp. 1-2) (Li 2013A). [cited by examiner]
Li et al., 2013 (Geneseq Accession No. BBC18586, computer printout, pp. 1-6) (Li 2013B). [cited by examiner]
Yang et al., 2013 (Geneseq Accession No. BAS77292, computer printout, pp. 1-3). [cited by examiner]
GenBank Accession No. BC060857, “ [cited by applicant]
Igarashi et al., “New innovations for ocular gene therapy,” Journal Medical Practitioners, 2017, 13(2):89-96 (English Abstract). [cited by applicant]
Nakano et al., “CYP4V2 in Bietti's crystalline dystrophy: ocular localization, metabolism of ω-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant,” Mol. Pharmacol., Oct. 2012, 82(4):679-686. [cited by applicant]
Nakano et al., “Expression and characterization of CYP4V2 as a fatty acid omega—hydroxylase,” Drug Metab. Dispos., Nov. 2009, 37(11):2119-2122. [cited by applicant]
Office Action in Japanese Appln. No. 2020-528530 dated Aug. 16, 2022, 23 pages (with English translation). [cited by applicant]
International Search Report mailed in International Application No. PCT/IB2018/055755 (Dec. 19, 2018). [cited by applicant]
Lai, Timothy Y.Y., et al., “Genotype-Phenotype Analysis of Bietti's Crystalline Dystrophy in Patients with CYP4V2 Mutations,” Investigative Ophthalmology & Visual Science (IOVS) Nov. 30, 2007, vol. 48:11, 5212-5220. [cited by applicant]
Park YJ et al., “ [cited by applicant]
“Predicted: Colobus angolensis palliatus cytochrome P450 4V2 (LOC105524323), mRNA,” NCBI Reference Sequence: XM_011959515.1 Mar. 30, 2015 https://www.ncbi.nlm.nih.gov/nuccore/XM_011959515.1. [cited by applicant]
Tashiro et al, “Unnamed Protein Product,” Genbank accession No. BAC85487.1 Jan. 9, 2008 https://www.ncbi.nlm.nih.gov/protein/BAC85487. [cited by applicant]
Hata et al., “Reduction of lipid accumulation rescues Bietti's crystalline dystrophy phenotypes,” PNAS, Mar. 26, 2018, 115(15):3936-3941. [cited by applicant]
Lockhart, “Function and Regulation of Cytochrome P450 4V2 and the Implications in Bietti's Crystalline Dystrophy,” Thesis for the degree of Doctor of Philosophy, University of Washington, Department of Pharmaceutics, Ju… [cited by applicant]
European Patent Office; Extended European Search Report mailed in corresponding European Patent Application No. 18842071.5 (May 21, 2021), 9 pages. [cited by applicant]
European Patent Office; Communication Pursuant to Article 94(3) EPC mailed in corresponding European Patent Application No. 18842071.5 (Apr. 13, 2022), 4 pages. [cited by applicant]
Office Action in Taiwanese Appln. No. 107126585, dated Dec. 15, 2022, 12 pages (with English translation). [cited by applicant]
Search Report in Taiwanese Appln. No. 107126585, mailed on Dec. 15, 2022, 2 pages (with English translation). [cited by applicant]
Office Action in Japanese Appln. No. 2020-528530 dated Apr. 12, 2023, 7 pages (with English translation). [cited by applicant]
Office Action in Korean Application No. 2020-7005930 dated Jun. 28, 2023, 17 pages (with English translation). [cited by applicant]
Office Action in New Zealand Application No. 761655 dated Aug. 7, 2023, 6 pages. [cited by applicant]
Office Action in Canadian Appln. No. 3071769, dated Oct. 16, 2023, 6 pages. [cited by applicant]
Office Action in Japanese Appln. No. 2020-528530, dated Jan. 23, 2024, 6 pages (with English translation). [cited by applicant]
Genbank Accession No. NP_997235.3, “cytochrome P450 4V2 [ [cited by applicant]
Office Action in Chinese Appln. No 201880064626.5, dated Oct. 30, 2023, 14 pages (with English translation). [cited by applicant]
McClements et al., “Gene therapy for retinal disease,” Translational Research, Apr. 2013, 161(4):241-254, 23 pages. [cited by applicant]
Office Action in Australian Application No. 2018311504, dated Oct. 5, 2023, 5 pages. [cited by applicant]
Agbandje-McKenna et al., “AAV capsid structure and cell interactions,” Methods. Mol. Biol., Jan. 2011, 807:47-92. [cited by applicant]
Asokan et al., “Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle,” NAT Biotechnol. Jan. 2010, 28(1):79-82. [cited by applicant]
Balaggan et al., “Stable and efficient intraocular gene transfer using pseudotyped EIA V lentiviral vectors,” J. Gene Med., Mar. 2006, 8(3):275-285. [cited by applicant]
Flannery et al., “Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus,” Proc.Natl. Acad. Sci. U.S.A., Jun. 1997, 94(13):6916-6921. [cited by applicant]
Gao et al., “Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy,” PNAS, Sep. 2002, 99(18):11854-11859. [cited by applicant]
Gurda et al., “Mapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8,” J. Virol., Aug. 2012, 86(15):7739-7751. [cited by applicant]
Hameed et al., “A New Locus for Autosomal Recessive RP (RP29) Mapping to Chromosome 4q32-q34 in a Pakistani Family,” Invest. Opthalmol. Vis. Sci., Jul. 2001, 42(7):1436-1438. [cited by applicant]
Kern et al., “Identification of a heparin-binding motif on adeno-associated virus type 2 capsids,” J. Virol., Oct. 2003, 77(20):11072-11081. [cited by applicant]
Lebkowski et al., “Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types,” Oct. 1988, Mol. Cell Biol. 8(10):3988-3996. [cited by applicant]
Li et al., “Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2,” Am. J. Hum. Genet., May 2004, 74(5):817-826. [cited by applicant]
Michaelides et al., “An Early-Onset Autosomal Dominant Macular Dystrophy (MCDR3) Resembling North Carolina Macular Dystrophy Maps to Chromosome 5,” Invest. Opthalmol. Vis. Sci., May 2003, 44(5):2178-2183. [cited by applicant]
Nam et al., “Structure of adeno-associated virus serotype 8, a gene therapy vector,” J. Virol., Nov. 2007, 81(22):12260-12271. [cited by applicant]
Ng et al., “Genetics of Bietti Crystalline Dystrophy,” Asia-Pacific Journal of Ophthalmology, Jul./Aug. 2016, 5(4):245-252. [cited by applicant]
Office Action in Australian Appln. No. 2018311504, dated May 23, 2024, 3 pages. [cited by applicant]
Office Action in Canadian Appln. No. 3,071,769, dated Jun. 12, 2024, 8 pages. [cited by applicant]
Office Action in Chinese Appln. No. 201880064626.5, mailed on Aug. 1, 2024, 25 pages (with English translation). [cited by applicant]
Office Action in European Appln. No. 18842071.5, dated May 10, 2024, 3 pages. [cited by applicant]
Office Action in Korean Appln. No. 10-2020-7005930, mailed on Jul. 31, 2024, 11 pages (with English translation). [cited by applicant]
Opie et al., “Identification of Amino Acid Residues in the Capsid Proteins of Adeno-Associated Virus Type 2 That Contribute to Heparan Sulfate Proteoglycan Binding,” J. Virol., Jun. 2003, 77(12):6995-7006. [cited by applicant]
Opposition in Japanese Patent No. 7448953, dated Apr. 17, 2024, 136 pages (with English translation). [cited by applicant]
Padron et al., “Structure of Adeno-Associated Virus Type 4,” J. Virol., Apr. 2005, 79(8):5047-5058. [cited by applicant]
Pang et al., “Efficiency of lentiviral transduction during development in normal and rd mice,” Mol. Vis., Jul. 2006, 12:56-67. [cited by applicant]
Takahashi, “Delivery of genes to the eye using lentiviral vectors,” Methods Mol. Biol., 2004, 246:439-449. [cited by applicant]
Thompson et al., “Mutations in the gene encoding lecithin retinol acyltransferase are associated with early-onset severe retinal dystrophy,” Nat. Genet., Jun. 2001, 28(2):123-124. [cited by applicant]
Vandenberghe et al., “Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey,” Sci. Transl. Med., Jun. 2011, 3(88):88ra54. [cited by applicant]
Vardi et al., “mGluR6 Transcripts in Non-neuronal tissues,” J. Histochem. Cytochem., Dec. 2011, 59(12):1076-1086. [cited by applicant]
Wang et al., “Sustained correction of bleeding disorder in hemophilia B mice by gene therapy,” 1999 Proc. Natl. Acad. Sci., USA, Mar. 1999, 96(7):3906-3910. [cited by applicant]
Wobus et al., “Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infectio… [cited by applicant]
Wu et al., “Adeno-associated virus serotypes: vector toolkit for human gene therapy,” Mol. Ther., Sep. 2006, 14(3):316-327. [cited by applicant]
Xie et al., “The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy,” PNAS, Aug. 2002, 99(16):10405-10410. [cited by applicant]
Yang, “A patient advocating for transparent science in rare disease research,” Orphanet Journal of Rare Diseases, Jan. 19, 2023, 18(1):14. [cited by applicant]
Kuzmin et al., “The clinical landscape for AAV gene therapies,” Nat. Rev. Drug. Discov., Mar. 2021, 20(3):173-174. [cited by applicant]
NCBI.gov [online], “CAG promoter,” retrieved on May 2022, retrieved from URL<https://ncbi.nlm.nih.gov/nuccore/?term=CAG+promoter>, 3 pages. [cited by applicant]
NCBI.gov [online], “EFS promoter,” retrieved on May 2022, retrieved from URL<https://ncbi.nlm.nih.gov/nuccore/?term=EFS+promoter>, 3 pages. [cited by applicant]
Nieuwenhuis et al., “Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters,” Gene Therapy, Jun. 2023, 30(6):503-519. [cited by applicant]
Third Party Observations in Chinese Appln. No. 201880064626.5, dated Oct. 16, 2024, 32 pages (with machine translation). [cited by applicant]
Zhang, “Retinitis Pigmentosa: Progress and Perspective,” Asia-Pacific Journal of Ophthalmology, Jul./Aug. 2016, 5(4):265-271. [cited by applicant]
Office Action in Australian Appln. No. 2018311504, mailed on Sep. 26, 2024, 3 pages. [cited by applicant]
Third Party Observation for Chinese Appln. No. 201880064626.5, mailed on Jul. 1, 2024, 10 pages (with English translation). [cited by applicant]
Third Party Observation for Chinese Appln. No. 201880064626.5, mailed on Mar. 22, 2024, 33 pages (with English translation). [cited by applicant]
Notification of Decision to Grant Patent in Chinese Appln. No. 201880064626.5, dated Dec. 23, 2024, 2 pages (with English translation). [cited by applicant]
Decision on Opposition in Japanese Appln. No. 2020-528530, dated Nov. 20, 2024, 49 pages (with machine translation). [cited by applicant]
Extended European Search Report in European Appln No. 24179907.1, dated Dec. 5, 2024, 8 pages. [cited by applicant]
A Guide to Human Gene Therapy, Herzog and Zolotukhin (eds.), Jun. 2010, 415 pages. [cited by applicant]
Barnard et al., “Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector,” Cold Spring Harb Perspect Med., Oct. 2014, 5(3):a017293, 16 pages. [cited by applicant]
Cereso et al., “Proof of concept for AAV2/5-mediated gene therapy in iPSC-derived retinal pigment epithelium of a choroideremia patient,” Mol. Ther. Methods Clin. Dev., Apr. 2014, 1:14011, 13 pages. [cited by applicant]
GenBank Accession No. AAR31180.1, “cytochrome p450 4V2 [ [cited by applicant]
Li et al., “Utilization of fundus autofluorescence, spectral domain optical coherence tomography, and enhanced depth imaging in the characterization of Bietti Crystalline Dystrophy in Different Stages,” Retina., Oct. 20… [cited by applicant]
Miyata et al., “Choroidal and retinal atrophy of Bietti Crystalline Dystrophy patients with CYP4V2 mutations compared to retinitis pigmentosa patients with EYS mutations,” Retina, The Journal of Retinal and Vitreous Dis… [cited by applicant]
Naso et al., “Adeno-Associated Virus (AAV) as a Vector for Gene Therapy,” BioDrugs., Jul. 2017, 31:317-334. [cited by applicant]
Office Action in Japanese Appln. No. 2024-025982, dated Apr. 1, 2025, 13 pages (with English translation). [cited by applicant]
Office Action in Korean Appln. No. 10-2020-7005930, dated Jan. 17, 2025, 8 pages (with English translation). [cited by applicant]
Opposition in European Patent No. EP3662066, dated Mar. 6, 2025, 51 pages. [cited by applicant]
Opposition in European Patent No. EP3662066, dated Mar. 7, 2025, 34 pages. [cited by applicant]
Schon et al., “Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications,” Eur. J. Pharm. Biopharm., Sep. 2015, 95(Part B):343-352. [cited by applicant]
Third Party Observation for Korean Appln. No. 10-2020-7005930, mailed on Jan. 9, 2025, 48 pages (with English translation). [cited by applicant]
Vasireddy et al., “AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models,” PLoS One, May 2013, 8(5):e61396, 13 pages. [cited by applicant]
Zhang et al., “Choroideremia is a systemic disease with lymphocyte crystals and plasma lipid and RBC membrane abnormalities,” Invest Ophthalmol. Vis. Sci., Dec. 2015, 56(13):8158-8156. [cited by applicant]
Adeno-related Viruses: From Virus to Clinical, Xu (ed.), 1st ed., Nov. 2014, 228 pages (with English Abstract and Table of Contents). [cited by applicant]
GenBank Accession No. EF591488.1, “Gene-trap donor vector pZGI, complete sequence,” Jun. 28, 2007, 5 pages. [cited by applicant]
Holehonnur et al., “The production of viral vectors designed to express large and difficult to express transgenes within neurons” Molecular Brain, Feb. 2015, 8:12, 20 pages. [cited by applicant]
Qu et al., “Progress in mechanism of CYP4V2 gene mutations for Bietti crystalline corneoretinal dystrophy,” Chin. J. Exp. Opthalmol., Aug. 2014, 32(8):756-759 (with English abstract). [cited by applicant]
Request for Invalidation in Chinese Appln. No. 201880064626.5, issued on Apr. 3, 2025, 162 pages (with machine translation). [cited by applicant]
Song et al., “Current clinical trials and progress of gene therapy for the treatment of inherited retinal degenerations,” Chin. J. Ocul. Fundus Dis., Nov. 2016, 32(6):650-654 (with English abstract). [cited by applicant]
Office Action in Taiwanese Appln. No. 112137422, issued on May 28, 2025, 31 pages (with machine translation). [cited by applicant]
Supplemental Request for Invalidation in Chinese Appln. No. 201880064626.5, issued on May 7, 2025, 35 pages (with machine translation). [cited by applicant]
Saatci et al., “Diagnostic and Management Strategies of Bietti Crystalline Dystrophy: Current Perspectives,” Clinical Ophthalmology, Mar. 2023, 2023(17):953-967. [cited by applicant]
Statement of Opinion submitted by the Petitioner, related to the Request of Invalidation Examination for the patent of Chinese Appln. No. 201880064626.5, issued on Jun. 10, 2025, 29 pages (in Chinese with English machin… [cited by applicant]
Wu et al., “Photochemical Damage of the Retina,” Survey of Ophthalmology, September-Oct. 2006, 51(5):461-480. [cited by applicant]
Statement of Opinion submitted by the Petitioner, related to the Request of Invalidation Examination for the Patent of Chinese Appln. No. 201880064626.5, issued on Jul. 10, 2025, 23 pages (with machine translation). [cited by applicant]
Amended Explanation of Evidence in the Invalidation Request for Japanese Patent No. 7448953, received on Oct. 27, 2025, 20 pages (with machine translation). [cited by applicant]
Amended Invalidation Request in Japanese Patent No. 7448953, received on Oct. 27, 2025, 261 pages (with machine translation). [cited by applicant]
Annex A as submitted on Aug. 22, 2022, Exhibit D37, Consolidated List in EP Appln. 18842071.5, 12 pages. [cited by applicant]
Annex B as submitted on Jan. 27, 2023, Exhibit D38, Consolidated List in EP Appln. 18842071.5, 2 pages. [cited by applicant]
Chang et al., “High-Fat Diet-Induced Retinal Dysfunction,” Invest. Ophthalmol. Vis. Sci., Apr. 2015, 56(4):2367-2380. [cited by applicant]
Choi et al., “Crystalline Maculopathy Associated With High-Dose Lutein Supplementation,” JAMA Ophthalmol., Dec. 2016, 134(12):1445-1448. [cited by applicant]
ClinicalTrialsArena.com [online], “Biogen's rare eye disease gene therapy falls short at Phase III,” Mar. 2022, retrieved on Nov. 2025, retrieved from URL<https://www.clinicaltrialsarena.com/news/biogens-rare-eye-diseas… [cited by applicant]
Decision on Invalidation Request in Chinese Appln. No. 201880064626.5, dated Nov. 6, 2025, 56 pages (with machine translation). [cited by applicant]
Dowling et al., “Inherited retinal dystrophy in the rat,” J. Cell Biol, Jul. 1962, 14(1):73-109. [cited by applicant]
Explaination of Evidence in the Invalidation Request for Japanese Patent No. 7448953, received on Oct. 27, 2025, 12 pages (with machine translation). [cited by applicant]
GenBank Accession No. AY422002.1, “Homo sapiens cytochrome P450 4V2 (CYP4V2) mRNA, complete cds,” dated Oct. 1, 2004, 3 pages. [cited by applicant]
GenBank Accession No. NP_997235.3, “cytochrome P450 4V2 [Homo sapiens],” Jun. 26, 2017, 3 pages. [cited by applicant]
GlobalGenes.org [online], “Biogen XLRP Gene Therapy Fails Late-Stage Study,” May 2021, retrieved on Nov. 2025, retrieved from URL <https://globalgenes.org/raredaily/biogen-xlrp-gene-therapy-fails-late-stage-study/>, 3 p… [cited by applicant]
Hata et al., “Reduction of lipid accumulation rescues Bietti's crystalline dystrophy phenotypes-Support Information,” PNAS, Mar. 26, 2018, 115(15):3936-3941, 11 pages. [cited by applicant]
Invalidation Request in Chinese Appln. No. 201880064626.5, dated Sep. 2, 2025, 4 pages (with machine translation). [cited by applicant]
Invalidation Request in Japanese Patent No. 7448953, received on Oct. 27, 2025, 252 pages (with machine translation). [cited by applicant]
Jia et al., “Unravelling CYP4V2: Clinical features, genetic insight, pahtogenic mechanisms and therapeutic strategies in Bietti crystalline corneoretinal dystrophy,” Progress in Retinal and Eye Research, Jun. 2025, 107(… [cited by applicant]
Kim et al., “The Effects of Metformin on Obesity-Induced Dysfunctional Retinas,” Invest. Opthalmoll. Vis. Sci., Jan. 2017, 58(1):106-118. [cited by applicant]
Kovach et al., “Crystalline retinopathy: Unifying pathogenic pathways of disease,” Survey of Ophthalmology, Jan.-Feb. 2019, 64(1):1-29, 84 pages. [cited by applicant]
Lockhart et al., “Generation and Characterization of a Murine Model of Bietti Crystalline Dystrophy,” Invest. Ophthalmol. Vis. Sci., Aug. 2014, 55(9):5572-5581. [cited by applicant]
Ludwig, “Mammalian Expression Cassette Engineering for High-Level Protein Production,” BioProcess International, May 2006, Supplement, 14-23, 9 pages. [cited by applicant]
Naash et al., “Light-induced acceleration of photreceptor degeneration in transgenic mice expressing mutant rhidispin,” Invest Ophthalmol. Vis. Sci., Apr. 1996, 37(5):775-782. [cited by applicant]
Organisciak et al., “Susceptibility to retinal light damage in transgenic rats with rhodospin mutations,” Invest. Ophthalmol. Vis. Sci., Feb. 2003, 44(2):486-492. [cited by applicant]
Patentee Reply in Response to the Communication pursuant to Rule 79(1) EPC dated Mar. 17, 2025, in Europepan Patent No. 3662066, submitted on Jul. 17, 2025, 218 pages. [cited by applicant]
Patentee Response to Request for Invalidation in Chinese Appln. No. 201880064626.5, dated Aug. 25, 2025, pages (with machine translation). [cited by applicant]
Patentee Response to Request for Invalidation in Chinese Appln. No. 201880064626.5, dated Jul. 10, 2025, 68 pages (with machine translation). [cited by applicant]
Patentee Response to Request for Invalidation in Chinese Appln. No. 201880064626.5, dated Jun. 9, 2025, 47 pages (with machine translation). [cited by applicant]
Patentee Response to Request for Invalidation in Chinese Appln. No. 201880064626.5, dated May 6, 2025, 115 pages (with machine translation). [cited by applicant]
Qu et al., “Trewating Bietti crystalline dystrophy in a high-fat diet exacerbated murine model using gene therapy,” Gene Ther., Aug. 2020, 27(7-8):370-382. [cited by applicant]
Statement of Opinion by Petitioner in Chinese Invalidation Request in Appln. No. 201880064626.5, dated Sep. 2, 2025, 60 pages (with machine translation). [cited by applicant]
Statement of Opinion by Petitioner in Chinese Invalidation Request in Appln. No. 201880064626.5, dated Jul. 24, 2025, 43 pages (with machine translation). [cited by applicant]
Stern et al., “Retinal pigment epithelial cell proliferation,” Exp. Biol. Med. (Maywood), Aug. 2015, 204(8):1079-1086. [cited by applicant]
Summons to Attend Oral Proceedings Pursuant to Rule 115(1) EPC in EP Appln. No. 18842071.5, dated Oct. 22, 2025, 39 pages. [cited by applicant]
Wang et al., “Expression of a mutant opsin gene increases the susceotibility of the retina to light damage,” Vis. Neurosci., Jan.-Feb. 1997, 14(1):55-62. [cited by applicant]
Written Amendment submitted in Japanese Patent No. 7448953, dated Feb. 15, 2023, 51 pages (with English translation). [cited by applicant]
Wu et al., “Generation of a human induced pluripotent stem cell line from a Bietti crystalline corneoretinal dystrophy patient with CYP4V2 mutations,” Stem Cell Research, May 2021, 53(2021):102330, 4 pages. [cited by applicant]
Yvon et al., “Using Stem Cells to Model Diseases of the Outer Retina,” Computational and Structural Biotechnology Journal, May 2015, 13(2015):382-389. [cited by applicant]
Office Action in Japanese Appln. No. 2024025982, dated Nov. 11, 2025, 10 pages (with English translation). [cited by applicant]
Examination Report in Indian Appln. No. 202017008657, dated Jan. 27, 2026, 15 pages. [cited by applicant]
Genbank Accession No. AC110771.3, “Homo sapiens BAC clone RP11-173M11 from 4, complete sequence,” Nov. 30, 2009, 40 pages. [cited by applicant]
Genbank Accession No. LT727128.1, “Mammalian expression vector pEF1-2FKBP-link-hFADD-DED, complete sequence,” Feb. 6, 2017, 4 pages. [cited by applicant]
Genbank Accession No. NM_207352.4, “Homo Sapiens Cytochrome P450 Family 4 Subfamily V Member 2, mRNA,” Nov. 22, 2018, 5 pages. [cited by applicant]
Stieger et al., “Adeno-associated virus mediated gene therapy for retinal degenerative disease,” Methods Mol Biol., Jan. 2011, 807:179-218. [cited by applicant]